Key focus areas of said development should seek to fully interrogate the therapeutic utility of disrupting MDM2 dimerization in MDM2/MDMX-dependent TP53 MT cancer, as well as the associated p53-independent mechanisms at play. The gene discussed is MDM2; the disease is cancer.